Glaukos Corporation Reveals Agreements To Exchange $230M In Principal Amount Of Its 2.75% Convertible Senior Notes Due 2027 For Common Stock; These Exchange Transactions Are Expected To Close On Or About June 25, 2024
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the "Exchange Agreements")
